Drug intelligence / Profile preview

BOW100

Development stage: Unknown
Lead developer: Epirus Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

**BOW100** is a biosimilar to golimumab, a fully human monoclonal antibody targeting tumor necrosis factor alpha (TNFα). Developed by EPIRUS Biopharmaceuticals, it is designed for the treatment of inflammatory conditions such as rheumatoid arthritis, with a mechanism of action identical to the reference product, neutralizing TNFα to reduce inflammation and joint damage. It remains in the preliminary stage of development, with limited clinical data available.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on BOW100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BOW100.

Explore the full profile